72 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase http://www.zacks.com/stock/news/372396/aeglea-agle-reports-new-positive-data-for-pegzilarginase?cid=CS-ZC-FT-372396 Apr 08, 2019 - Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer http://www.zacks.com/stock/news/377515/astrazeneca-mercks-lynparza-wins-eu-nod-for-breast-cancer?cid=CS-ZC-FT-377515 Apr 10, 2019 - AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Seattle Genetics' Adcetris Progresses Well Amid Competition http://www.zacks.com/stock/news/379195/seattle-genetics-adcetris-progresses-well-amid-competition?cid=CS-ZC-FT-379195 Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Merck & Co Inc (MRK) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/30/merck-co-inc-mrk-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 30, 2019 - MRK earnings call for the period ending March 31, 2019.
Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress http://www.zacks.com/stock/news/408282/dow-30-stock-roundup-aapl-pfe-mrk-mcd-earnings-impress?cid=CS-ZC-FT-408282 May 03, 2019 - The index traversed a mixed week, buoyed by encouraging earnings numbers and dragged lower by comments from the Fed Chair.
Top Analyst Reports for Berkshire Hathaway, Merck & Charter Communications http://www.zacks.com/research-daily/410193/top-analyst-reports-for-berkshire-hathaway-merck-charter-communications?cid=CS-ZC-FT-410193 May 07, 2019 - Top Analyst Reports for Berkshire Hathaway, Merck & Charter Communications
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More http://www.zacks.com/stock/news/411198/drug-biotech-stock-q1-earnings-on-may-9-ions-xlrn-more?cid=CS-ZC-FT-411198 May 08, 2019 - Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

Pages: 12345678

<<<Page 3>